Phase 2
Completed N=90
Topical Endoxifen in Women
Mammographic Breast Density
Source: ClinicalTrials.gov NCT04616430 ↗
Enrolled (actual)
90
Serious AEs
0.0%
Results posted
Jun 2021
Primary outcomePrimary: Change in Mammographic Breast Density At Study Exit — -1.85; -2.14; -3.75 percent change from baseline
Summary
Karma CREME-1 consisted of 90 participants from the Karma Cohort. The major focus of the pilot trial was to estimate time to mammographic density change. The primary objective was to determine the effect size of the breast density change between topical placebo and two doses of topical endoxifen.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Mammographic Breast Density At Study Exit |
-1.85; -2.14; -3.75 | — |
Eligibility Criteria
Inclusion Criteria
- Participant in the Karma Cohort
- Attending the national mammography screening program, i.e., aged 40-74 and have performed a screening mammogram maximum 3 months prior to study inclusion
- Mammographic density ~4.5 % density (volumetric) measured by Volpara, at the screening mammogram performed in connection to baseline (maximum 3 months prior to inclusion). The threshold value of 4.5% corresponds to the clinical Bl-RADS score A
- Postmenopausal, defined as no period of menstruation during last 12 months independent of any hormonal treatment
- Informed consent must be signed before any study specific assessments are performed
Exclusion Criteria
- Any previous or current diagnosis of breast cancer (including carcinoma in situ).
- Any previous diagnosis of cancer with the exception of non-melanoma skin cancer and in situ cancer of the cervix.
- A history of major surgery of the breast, e.g., reduction or enlargement, which might affect density measurements.
- Mammographic Bl-RADS malignancy code 3, or above, at baseline mammography, or at mammography during time of treatment. Recall for additional examinations due to technical problems with the mammogram is accepted.
- Currently using estrogen and progesterone based hormone replacement therapy (oral or patches). Local estrogen treatment is accepted (ex. Vagifem).
- Non-medical approved drugs against hot-flashes including phytoestrogen.
Data sourced from ClinicalTrials.gov (NCT04616430). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.